 Zynerba Pharmaceuticals Inc NASDAQ:ZYNE believes its operations and capital requirements to be fully funded into 2024, the company announced as part of its fourth quarter and full-year results published Wednesday. As of December 31, the company had 59.2 million in cash and equivalents on hand, compared to 70.9 million on the same day a year earlier. 